Idiopathic pulmonary fibrosis: Novel concepts of proton pump inhibitors as antifibrotic drugs

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 12, 2016, Pages 1345-1352

  Ghebre, Yohannes T ^a   Raghu, Ganesh ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antireflux Surgery; Fibrosis; Gastroesophageal Reflux; Lung Inflammation; Proton Pump Inhibitors

Indexed keywords

ANTIFIBROTIC AGENT; PROTON PUMP INHIBITOR; ANTIFIBRINOLYTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; LUNG FUNCTION; LUNG INJURY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STOMACH FUNDOPLICATION; STOMACH JUICE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY;

ANTIFIBRINOLYTIC AGENTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PROTON PUMP INHIBITORS; RESPIRATORY FUNCTION TESTS;

EID: 84988865144     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201512-2316PP     Document Type: Review

References (64)

1. Duke University. Lung and diaphragm development. 2015 [accessed 2015 Nov 20]. Available from: https://web.duke.edu/anatomy/embryology/respiratory/lungDiaphragm.html
2. Tobin RW, Pope CE II, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158: 1804-1808.
3. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE II, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-142.
4. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastrooesophageal reflux disease: A systematic review. Gut 2005;54:710-717.
5. Robinson NB, DiMango E. Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease. Ann Am Thorac Soc 2014;11:964-968.
6. Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: A systematic review. Gut 2007;56:1654-1664.
7. Mokhlesi B, Morris AL, Huang CF, Curcio AJ, Barrett TA, Kamp DW. Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest 2001;119:1043-1048.
8. Kim J, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH, Rhee CK, Yoon HK, Kim YS, Park YB, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: A national cross-sectional cohort study. BMC Pulm Med 2013;13:51.
9. King BJ, Iyer H, Leidi AA, Carby MR. Gastroesophageal reflux in bronchiolitis obliterans syndrome: A new perspective. J Heart Lung Transplant 2009;28:870-875.
10. Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with tracheobronchial aspiration: A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976;69:512-515.
11. Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A, Damani T, Way LW. Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg 2005;9:1053-1056, discussion 1056-1058.
12. Salvioli B, Belmonte G, Stanghellini V, Baldi E, Fasano L, Pacilli AM, De Giorgio R, Barbara G, Bini L, Cogliandro R, et al. Gastrooesophageal reflux and interstitial lung disease. Dig Liver Dis 2006; 38:879-884.
13. Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, Theodore PR. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007;133:1078-1084.
14. Gao F, Hobson AR, Shang ZM, Pei YX, Gao Y, Wang JX, Huang WN. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis. BMC Gastroenterol 2015;15:26.
15. Blondeau K, Mertens V, Vanaudenaerde BA, Verleden GM, Van Raemdonck DE, Sifrim D, Dupont LJ. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J 2008;31:707-713.
16. Perng DW, Chang KT, Su KC, Wu YC, Wu MT, Hsu WH, Tsai CM, Lee YC. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: A relation to transforming growth factor-beta1 production and fibroblast proliferation. Chest 2007;132:1548-1556.
17. DOvidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, Hadjiliadis D, Chaparro C, Gutierrez C, Pierre A, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005;129: 1144-1152.
18. Bathoorn E, Daly P, Gaiser B, Sternad K, Poland C, Macnee W, Drost EM. Cytotoxicity and induction of inflammation by pepsin in acid in bronchial epithelial cells. Int J Inflam 2011;2011:569416.
19. Perng DW, Wu YC, Tsai CC, Su KC, Liu LY, Hsu WH, Lee YC. Bile acids induce CCN2 production through p38 MAP kinase activation in human bronchial epithelial cells: A factor contributing to airway fibrosis. Respirology 2008;13:983-989.
20. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999;21:693-700.
21. Beck-Schimmer B, Rosenberger DS, Neff SB, Jamnicki M, Suter D, Fuhrer T, Schwendener R, Booy C, Reyes L, Pasch T, et al. Pulmonary aspiration: new therapeutic approaches in the experimental model. Anesthesiology 2005;103:556-566.
22. Folkesson HG, Matthay MA, Hébert CA, Broaddus VC. Acid aspirationinduced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms. J Clin Invest 1995;96:107-116.
23. Kennedy TP, Johnson KJ, Kunkel RG, Ward PA, Knight PR, Finch JS. Acute acid aspiration lung injury in the rat: biphasic pathogenesis. Anesth Analg 1989;69:87-92.
24. Johnston N, Wells CW, Blumin JH, Toohill RJ, Merati AL. Receptormediated uptake of pepsin by laryngeal epithelial cells. Ann Otol Rhinol Laryngol 2007;116:934-938.
25. Mertens V, Blondeau K, Vanaudenaerde B, Vos R, Farre R, Pauwels A, Verleden G, Van Raemdonck D, Dupont L, Sifrim D. Gastric juice from patients "on" acid suppressive therapy can still provoke a significant inflammatory reaction by human bronchial epithelial cells. J Clin Gastroenterol 2010;44:e230-e235.
26. Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis 1986;133:913-927.
27. Kao SJ, Su CF, Liu DD, Chen HI. Endotoxin-induced acute lung injury and organ dysfunction are attenuated by pentobarbital anaesthesia. Clin Exp Pharmacol Physiol 2007;34:480-487.
28. Rojas M, Woods CR, Mora AL, Xu J, Brigham KL. Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. Am J Physiol Lung Cell Mol Physiol 2005;288:L333-L341.
29. Noth I, Zangan SM, Soares RV, Forsythe A, Demchuk C, Takahashi SM, Patel SB, Strek ME, Krishnan JA, Patti MG, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012;39:344-351.
30. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS, Collard HR. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012;39:352-358.
31. Farhath S, He Z, Nakhla T, Saslow J, Soundar S, Camacho J, Stahl G, Shaffer S, Mehta DI, Aghai ZH. Pepsin, a marker of gastric contents, is increased in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatrics 2008;121:e253-e259.
32. Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: Advancing the role of pepsin. Int J Otolaryngol 2012;2012:646901.
33. Farhath S, Aghai ZH, Nakhla T, Saslow J, He Z, Soundar S, Mehta DI. Pepsin, a reliable marker of gastric aspiration, is frequently detected in tracheal aspirates from premature ventilated neonates: relationship with feeding and methylxanthine therapy. J Pediatr Gastroenterol Nutr 2006;43:336-341.
34. Rosen R, Johnston N, Hart K, Khatwa U, Nurko S. The presence of pepsin in the lung and its relationship to pathologic gastroesophageal reflux. Neurogastroenterol Motil 2012;24:129-133, e84-e85.
35. Nissen R. Gastropexy and "fundoplication" in surgical treatment of hiatal hernia. Am J Dig Dis 1961;6:954-961.
36. Dallemagne B, Weerts J, Markiewicz S, Dewandre JM, Wahlen C, Monami B, Jehaes C. Clinical results of laparoscopic fundoplication at ten years after surgery. Surg Endosc 2006;20:159-165.
37. Patti MG, Arcerito M, Tamburini A, Diener U, Feo CV, Safadi B, Fisichella P, Way LW. Effect of laparoscopic fundoplication on gastroesophageal reflux disease-induced respiratory symptoms. J Gastrointest Surg 2000;4:143-149.
38. Allen CJ, Anvari M. Does laparoscopic fundoplication provide longterm control of gastroesophageal reflux related cough? Surg Endosc 2004;18:633-637.
39. Hoppo T, Jarido V, Pennathur A, Morrell M, Crespo M, Shigemura N, Bermudez C, Hunter JG, Toyoda Y, Pilewski J, et al. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation. Arch Surg 2011;146:1041-1047.
40. Linden PA, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT, Sugarbaker DJ, Bueno R. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006;131:438-446.
41. ClinicalTrials.gov. Treatment of IPF with laparoscopic anti-reflux surgery (WRAP-IPF). Clinical Trials identifier: NCT01982968 [accessed 18 Nov 2015]. Available from: www.clinicaltrials.gov
42. Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012;39:242-245.
43. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: A review and discussion of the clinical implications. Dig Dis Sci 2009;54:2312-2317.
44. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, Adachi S, Handa O, Kokura S, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-Associating protein 1. J Pharmacol Exp Ther 2009;331:255-264.
45. Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, Kondo M. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14:74-81.
46. Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, Nishimura H, Sasaki H. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol 2005;509:201-210.
47. Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, Moeller BC, Zhou Q, Ho L, de Andrade J, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med 2015; 13:249.
48. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: A case series. Chest 2006;129:794-800.
49. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390-1394.
50. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G; IPFnet Investigators. Anti-Acid treatment and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1: 369-376.
51. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al.; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-e19.
52. Raghu G, Crestani B, Bailes Z, Schlenker-Herceg R, Costabel U. Effect of anti-Acid medication on reduction in FVC decline with nintedanib. Presented at the European Respiratory Society Annual Meeting. September 26-30, 2015, Amsterdam, the Netherlands.
53. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-Acquired pneumonia: A population-based case-control study. Arch Intern Med 2007;167:950-955.
54. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol 2016;73:410-416.
55. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014;177:292-297.
56. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. Plos One 2015;10:e0124653.
57. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, Teare GF, Ravani P, Ernst P, Dormuth CR; CNODES Investigators. Proton pump inhibitors and the risk of hospitalisation for communityacquired pneumonia: replicated cohort studies with meta-Analysis. Gut 2014;63:552-558.
58. Pei Z, Yang L, Peek RM, Jr Levine SM, Pride DT, Blaser MJ. Bacterial biota in reflux esophagitis and Barretts esophagus. World J Gastroenterol 2005;11:7277-7283.
59. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009;137:588-597.
60. Liu N, Ando T, Ishiguro K, Maeda O, Watanabe O, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H. Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barretts esophagus. BMC Infect Dis 2013;13:130.
61. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, et al.; COMET Investigators. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: An analysis of the COMET study. Lancet Respir Med 2014;2:548-556.
62. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;190:906-913.
63. Molyneaux PL, Maher TM. Respiratory microbiome in IPF: cause, effect, or biomarker? Lancet Respir Med 2014;2:511-513.
64. Tcherakian C, Cottin V, Brillet PY, Freynet O, Naggara N, Carton Z, Cordier JF, Brauner M, Valeyre D, Nunes H. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66:226-231.